Remdesivir
Antiviral drug
Why this is trending
Interest in “Remdesivir” spiked on Wikipedia on 2026-02-25.
Categorised under Science & Nature, this article fits a familiar pattern. Science and technology topics tend to trend after breakthroughs, space missions, health announcements, or widely shared research findings.
GlyphSignal tracks these patterns daily, turning raw Wikipedia traffic data into a curated feed of what the world is curious about. Every spike tells a story.
Key Takeaways
- Remdesivir , sold under the brand name Veklury , is a broad-spectrum antiviral medication developed by the biopharmaceutical company Gilead Sciences.
- During the COVID‑19 pandemic, remdesivir was approved or authorized for emergency use to treat COVID‑19 in numerous countries.
- Remdesivir is a prodrug that is intended to allow intracellular delivery of GS-441524 monophosphate and subsequent biotransformation into GS-441524 triphosphate, a ribonucleotide analogue inhibitor of viral RNA polymerase.
- The most common side effect in people with COVID‑19 is nausea.
- The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Remdesivir, sold under the brand name Veklury, is a broad-spectrum antiviral medication developed by the biopharmaceutical company Gilead Sciences. It is administered via injection into a vein. During the COVID‑19 pandemic, remdesivir was approved or authorized for emergency use to treat COVID‑19 in numerous countries.
Remdesivir was originally developed to treat hepatitis C, and was subsequently investigated for Ebola virus disease and Marburg virus infections before being studied as a post-infection treatment for COVID‑19.
Remdesivir is a prodrug that is intended to allow intracellular delivery of GS-441524 monophosphate and subsequent biotransformation into GS-441524 triphosphate, a ribonucleotide analogue inhibitor of viral RNA polymerase.
The most common side effect in healthy volunteers is raised blood levels of liver enzymes. The most common side effect in people with COVID‑19 is nausea. Side effects may include liver inflammation and an infusion-related reaction with nausea, low blood pressure, and sweating.
The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Medical uses
In the European Union, remdesivir is indicated for the treatment of COVID‑19 in adults and adolescents (aged twelve years and older with body weight at least 40 kilograms (88 lb)) with pneumonia requiring supplemental oxygen and for adults who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID‑19.
In the United States, remdesivir is indicated for the treatment of COVID‑19 in people 28 days of age and older and weighing at least 3 kilograms (6.6 lb) who are hospitalized; or not hospitalized and have mild-to-moderate COVID‑19, and are at high risk for progression to severe COVID‑19, including hospitalization or death.
Content sourced from Wikipedia under CC BY-SA 4.0
